The ENZAMET trial represents a landmark achievement in prostate cancer research, demonstrating significant survival benefits for men with metastatic hormone-sensitive prostate cancer (mHSPC). This international phase III study, led by ANZUP in collaboration with the NHMRC Clinical Trials Centre, established enzalutamide as an important addition to first-line androgen deprivation therapy (ADT), showing improved outcomes compared with standard treatment alone.

Clinical Takeaway

The ENZAMET trial demonstrates that adding enzalutamide to standard androgen deprivation therapy in men with newly diagnosed mHSPC provides substantial clinical benefits, including a 33% improvement in overall survival and a 60% improvement in the time to detection of cancer progression. These results significantly exceeded initial expectations and established enzalutamide as an important first-line treatment option for this patient population.

Drug Profile & Mechanism

Enzalutamide is an oral androgen receptor antagonist that blocks multiple steps in the androgen receptor signaling pathway. The drug has previously demonstrated efficacy in advanced prostate cancer settings after progression on standard hormone therapy and chemotherapy, but ENZAMET represents the first major study to establish its role in the first-line metastatic setting.

Target Population

The ENZAMET trial enrolled men with newly diagnosed metastatic prostate cancer who were starting androgen deprivation therapy. This represents patients with hormone-sensitive disease who have cancer that has spread beyond the prostate but has not yet developed resistance to hormone treatment.

Study Design

  • Study Type: International, multicenter, randomized phase III trial
  • Sample Size: 1,125 participants
  • Geographic Scope: Australia, New Zealand, Canada, United States, Ireland, and United Kingdom
  • Protocol Number: ANZUP 1304
  • Study Chairs: Professor Ian Davis and Professor Christopher Sweeney
  • Status: Currently in follow-up phase

Primary Efficacy Outcomes

  • Overall Survival: 33% improvement compared with standard treatment alone
  • Time to Cancer Progression: 60% improvement in the time to detection of cancer growth
  • Quality of Life: Improved quality-of-life outcomes reported with enzalutamide treatment

These results significantly exceeded the initial expectations when the trial was designed, representing better-than-anticipated efficacy for the combination approach.

Trial Recognition

In 2020, the ENZAMET trial received unprecedented recognition from the Australian Clinical Trials Alliance (ACTA), winning all three major awards:

  • ACTA Trial of the Year Award
  • ACTA STInG Award for Excellence in Trial Statistics
  • Consumer Involvement Award

Key Clinical Implications

✔ First-line treatment option: Enzalutamide combined with androgen deprivation therapy is now established as an effective first-line treatment for mHSPC

✔ Substantial survival benefit: The 33% improvement in overall survival represents a clinically meaningful advancement for this patient population

✔ Delayed disease progression: Enzalutamide significantly prolonged the time before cancer growth was detected

✔ Quality of life benefits: Demonstrated improvements in patient-reported outcomes support the clinical utility of the combination approach

Bottom Line

The ENZAMET trial demonstrated that adding enzalutamide to androgen deprivation therapy improves outcomes for men with mHSPC. The study showed a 33% improvement in survival and a substantial delay in disease progression compared with standard treatment alone. These findings helped establish enzalutamide as an important first-line treatment option and represent a major contribution from an Australian-led international collaboration.

Sources: